secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-09-30T23:59:59+00:00
Accession:  0001140361-25-036637
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics LCA5 gene therapy shows 0.3 logMAR improvement in pediatric cohort; durable 18-month adult data
--------------------------------------------------------------------------------

- Three pediatric participants (ages 16-17) showed group avg 0.3 logMAR visual acuity improvement and >1 log unit cone sensitivity improvement on FST.
- All three pediatric participants improved on mobility test; microperimetry showed improved fixation in one evaluable participant.
- Adult data (3 participants) show visual acuity improvements sustained through 18 months; therapy well-tolerated with no ocular SAEs.
- Company expects to meet with FDA in Q4 2025 to discuss results and next steps for OPGx-LCA5 program.
- No ocular serious adverse events or dose-limiting toxicities; all ocular AEs mild, anticipated, not related to study drug.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125036637/0001140361-25-036637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125036637/ef20056246_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-036637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer